Float Short %

13.54

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

0.01

EPS Last/This Y

1.73

EPS This/Next Y

0.08

Price

0.28

Target Price

5.5

Analyst Recom

Performance Q

-46.09

Upside

-23,850.0%

Beta

0.79

Ticker: PSTV

19 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	PSTV	0.272	N/A	N/A	0
2026-01-26	PSTV	0.2516	N/A	N/A	0
2026-01-27	PSTV	0.238	N/A	N/A	0
2026-01-28	PSTV	0.2482	N/A	N/A	0
2026-01-29	PSTV	0.241	N/A	N/A	0
2026-01-30	PSTV	0.2289	N/A	N/A	0
2026-02-02	PSTV	0.2382	N/A	N/A	0
2026-02-03	PSTV	0.2397	N/A	N/A	0
2026-02-04	PSTV	0.2404	N/A	N/A	0
2026-02-05	PSTV	0.2309	N/A	N/A	0
2026-02-06	PSTV	0.2569	N/A	N/A	0
2026-02-09	PSTV	0.2568	N/A	N/A	0
2026-02-10	PSTV	0.2645	N/A	N/A	0
2026-02-11	PSTV	0.2686	N/A	N/A	0
2026-02-12	PSTV	0.2596	N/A	N/A	0
2026-02-13	PSTV	0.2754	N/A	N/A	0
2026-02-17	PSTV	0.2783	N/A	N/A	0
2026-02-18	PSTV	0.2815	N/A	N/A	0
2026-02-20	PSTV	0.2806	N/A	N/A	0
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

19 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	PSTV	0.27	91.8	-	-0.23
2026-01-26	PSTV	0.25	91.8	-	-0.23
2026-01-27	PSTV	0.24	91.8	-	-0.23
2026-01-28	PSTV	0.25	91.8	-	-0.23
2026-01-29	PSTV	0.24	91.8	-	-0.23
2026-01-30	PSTV	0.23	91.8	-	-0.23
2026-02-02	PSTV	0.24	91.8	-	-0.23
2026-02-03	PSTV	0.24	91.8	-	-0.23
2026-02-04	PSTV	0.24	91.8	-	-0.23
2026-02-05	PSTV	0.23	91.8	-	-0.23
2026-02-06	PSTV	0.26	91.8	-	-0.23
2026-02-09	PSTV	0.26	92.5	-	-0.23
2026-02-10	PSTV	0.26	92.5	-	-0.23
2026-02-11	PSTV	0.27	92.5	-	-0.23
2026-02-12	PSTV	0.26	92.5	-	-0.23
2026-02-13	PSTV	0.27	92.5	-	-0.23
2026-02-17	PSTV	0.28	92.5	-	-0.23
2026-02-18	PSTV	0.28	92.5	-	-0.23
2026-02-19	PSTV	0.29	92.5	-	-0.23
2026-02-20	PSTV	0.28	92.5	-	-0.23
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

19 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	PSTV	17.47	4.60	4.13
2026-01-26	PSTV	17.47	3.39	4.13
2026-01-27	PSTV	17.47	3.39	4.13
2026-01-28	PSTV	17.47	3.39	6.40
2026-01-29	PSTV	17.47	3.39	6.40
2026-01-30	PSTV	17.47	3.39	6.40
2026-02-02	PSTV	17.47	3.42	6.40
2026-02-03	PSTV	17.47	3.42	6.40
2026-02-04	PSTV	17.47	3.42	6.40
2026-02-05	PSTV	17.47	3.42	6.40
2026-02-06	PSTV	17.47	3.42	6.40
2026-02-10	PSTV	17.47	2.82	6.40
2026-02-11	PSTV	17.47	2.82	13.55
2026-02-12	PSTV	17.47	2.82	13.54
2026-02-13	PSTV	23.73	2.82	13.54
2026-02-17	PSTV	23.73	1.72	13.54
2026-02-18	PSTV	23.73	1.72	13.54
2026-02-19	PSTV	23.73	1.72	13.54
2026-02-20	PSTV	23.73	1.72	13.54
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

19 items 1 of 1

Last Quarter Act. EPS

-0.04

Avg. EPS Est. Current Quarter

-0.04

Avg. EPS Est. Next Quarter

-0.03

Insider Transactions

23.73

Institutional Transactions

1.72

Beta

0.79

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

99.5

Max Drawdown 5-Year %

-99.7

Target Price

5.5

P/E

Forward P/E

PEG

P/S

9.33

P/B

7.16

P/Free Cash Flow

EPS

-1.9

Average EPS Est. Cur. Y

-0.23

EPS Next Y. (Est.)

-0.15

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-466.64

Relative Volume

0.36

Return on Equity vs Sector %

-436.1

Return on Equity vs Industry %

-418.7

EPS 1 7Days Diff

0.1

EPS 1 30Days Diff

0.02

EBIT Estimation

PLUS THERAPEUTICS, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 21

Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.

stock quote shares PSTV – Plus Therapeutics Inc Stock Price stock today

news today PSTV – Plus Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025

marketwatch PSTV – Plus Therapeutics Inc yahoo finance google finance

stock history PSTV – Plus Therapeutics Inc invest stock market

stock prices PSTV premarket after hours

ticker PSTV fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PSTV

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y